Published 2022 | Version v1
Journal article

Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI. A real-life multicentric study

  • 1. Nuclear Medicine Division, Salus Alliance Medical, Genoa (Italy)
  • 2. Associazione Italiana Medicina Nucleare (AIMN), Pediatric Study Group, Milan (Italy)
  • 3. Medicine Unit, A.R.N.A.S. Ospedali Civico, Di Cristina E Benfratelli, Palermo (Italy)
  • 4. Imaging Department, Nuclear Medicine Unit, IRCCS Bambino Gesù Pediatric Hospital, Piazza Sant'Onofrio 4, 00165, Rome (Italy)
  • 5. Department of Nuclear Medicine, E.O. "Ospedali Galliera", Mura delle Cappuccine 14, 16128, Genoa (Italy)
  • 6. Department of Pediatrics, IRCCS Istituto Giannina Gaslini, Genova (Italy)
  • 7. Nuclear Medicine Unit, University Hospital "G. Martino", Messina (Italy)
  • 8. Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina (Italy)
  • 9. Nuclear Medicine Department, Azienda Ospedaliera Universitaria Di Modena, Modena (Italy)
  • 10. Nuclear Medicine Unit, Oncological Medical and Specialist Department, University Hospital of Ferrara, Ferrara (Italy)
  • 11. Department of Nuclear Medicine, ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, Varese (Italy)
  • 12. Endocrine Pathology of Chronic and Post Cancer Diseases Unit, IRCCS Bambino Gesù Pediatric Hospital, Piazza Sant'Onofrio 4, 00165, Rome (Italy)
  • 13. Nuclear Medicine Department, University of Brescia and ASST Spedali Civili Di Brescia, P.le Spedali Civili 1, 25123, Brescia (Italy)

Description

This multicentric study aimed to investigate the main prognostic factors associated with treatment response at 1 year after radioactive iodine therapy (RAIT) and the last disease status in pediatric patients affected by differentiated thyroid carcinoma (DTC). In the period 1990-2020, all consecutive patients 18 years from six different centers were retrospectively included. Patients were classified as low, intermediate, and high risk for persistence/recurrence. The response to RAIT was evaluated and scored 1 year later according to 2015 ATA guidelines. Moreover, at the last follow-up, the disease status was evaluated and dichotomized as no evidence of disease (NED) or persistent disease. Two hundred and eighty-five patients (197 female, 88 male; mean age 14.4 years) were recruited. All, except nine, underwent near-total thyroidectomy followed by RAIT. One-year after first RAIT, 146/276 (53%) patients had excellent response, 37/276 (14%) indeterminate response, and 91/276 (33%) incomplete response. One-year after RAIT, children with excellent response had significantly lower stimulated thyroglobulin (sTg) compared to not excellent group (median sTg 4.4 ng/ml vs 52.5 ng/ml, p < 0.001). ROC curve showed sTg higher than 27.2 ng/ml as the most accurate to predict 1-year treatment response. After a median follow-up of 133 months, NED was present in 241 cases (87%) while persistent disease in 35 (13%). At multivariate analysis, sTg and 1-year treatment response categories were both significantly associated with the last disease status (p value 0.023 and < 0.001). In pediatric DTC, sTg is significantly associated with 1-year treatment response and final outcome. However, 1-year response is the principal prognostic factor able to predict pediatric DTCs outcome.

Availability note (English)

Available from: http://dx.doi.org/10.1007/s00259-021-05586-8

Additional details

Identifiers

Publishing Information

Journal Title
European Journal of Nuclear Medicine and Molecular Imaging
Journal Volume
49
Journal Issue
4
Journal Page Range
p. 1374-1385
ISSN
1619-7070
CODEN
EJNMA6

Optional Information

Notes
Dosimetry